Podcast appearances and mentions of Aspen Pharmacare

Canadians who swore off U.S. travel in response to tariffs are evidently quite serious about their pledge, and airlines are starting to feel the impact. Drug makers like Aspen Pharmacare, Sandoz Group, and Hikma Pharmaceuticals are racing to put out cheaper, generic versions of popular drugs used for weight loss. Celebrating something? Let us know here: https://thepeak.typeform.com/to/MNdYA3TO

Stephen Grootes speaks to Sean Capazorio from Aspen Pharmacare, Wikus Olivier from Santam, Mpumi Madisa from Bidvest, and Dr. Leila Fourie from the JSE, to discuss their respective companies' latest financial results and the key drivers behind their performances. In other interviews, Ian Mann, Managing Director at Gateways Business Consultants, talks about his insights on Tribes by Michael Morris, exploring the book's key takeaways and relevance to the business world. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape. Thank you for listening to The Money Show podcast. Listen live - The Money Show with Stephen Grootes is broadcast weekdays between 18:00 and 20:00 (SA Time) on 702 and CapeTalk. There’s more from the Money Show on Primediaplus.com Subscribe to the Money Show daily and weekly newsletters The Money Show is brought to you by Absa. Follow us here 702 on Facebook: www.facebook.com/TalkRadio702 702 on TikTok: www.tiktok.com/@talkradio 702 on Instagram: www.instagram.com/talkradio702 702 on X: www.x.com/Radio702 702 on YouTube: www.youtube.com/@radio702 CapeTalk on Facebook: www.facebook.com/CapeTalk CapeTalk on TikTok: www.tiktok.com/@capetalk CapeTalk on Instagram: www.instagram.com/capetalkza CapeTalk on YouTube: www.youtube.com/@CapeTalk567 CapeTalk on X: www.x.com/CapeTalk See omnystudio.com/listener for privacy information.

Sean Capazorio – CFO, Aspen Pharmacare SAfm Market Update - Podcasts and live stream

Stavros Nicolaou Aspen Pharmacare Group's Senior Executive responsible for Strategic Trade Development discusses the PinkDrive initiative, the challenge of access to sufficient treatment, and the significance of corporate partnerships in tackling the public health crisis.See omnystudio.com/listener for privacy information.

Noluthando Mthonti-Mlambo speaks to Sean Capazorio, CFO at Aspen PharmacareSee omnystudio.com/listener for privacy information.

Nhlanhla Sehume speaks to Sean Capazorio, CFO of Aspen Pharmacare about the company's results. See omnystudio.com/listener for privacy information.

Noluthando Mthonti-Mlambo speaks to Sean Capazorio, Group Finance Officer, Aspen Pharmacare about their expansion plans in China.See omnystudio.com/listener for privacy information.

George Glynos, head of research at ETM Analytics gave an update on the two-pot retired system.      Sean Capazorio, group chief financial officer at Aspen Pharmacare on it concluding two significant agreements with Sandoz for China and Europe.   Justice Mukheli, multidisciplinary artist discussed how he makes his money through his various career disciplines.See omnystudio.com/listener for privacy information.

On this episode of Stock Picks, we take a look at Netcare, Life Healthcare and Aspen Pharmacare with Wessel Joubert from Oyster Catcher Investments. Stock Watch

The African SAP User Group (AFSUG) is a community-driven, non-profit organisation independent of SAP that represent the interests of SAP customers and partners in Africa. It does this by providing a platform to share stories, best practices and insights related to their experiences with SAP technology, assisting SAP users to address their key challenges in the African context. Africa trails other regions in terms of digital adoption and maturity. There are many reasons for this, including poor internet infrastructure and coverage, lack of trust in digital service providers, and a lack of digital and general technology skills. African companies must also overcome a myriad internal factors that contribute to low digital maturity, including cultural resistance to adopting digital tools, a lack of organisational agility required to adopt digital tools effectively, and underdeveloped technology capabilities. Despite these wide digital gaps and other challenges, there is clearly a desire to catch up to the rest of the world, and digital adoption and the associated infrastructure buildouts are occurring faster in Africa than in other regions. Through events, forums and networking opportunities, AFSUG allows SAP customers and partners from diverse industries across Africa to engage around these challenges and to exchange ideas to address them, accelerating successful business implementations. Aside from unlimited access to like-minded professionals, resources and education, a further benefit for AFSUG members is being able to influence SAP's direction in Africa and globally. Saphila 2023 Saphila, meaning “Alive”, is AFSUG's world-class biennial African conference, hosted in collaboration with SAP, and is making its post-pandemic comeback from 9-11 July 2023 at the Sun City resort in South Africa's North West province. This year's Saphila conference will also be the first-ever hybrid Saphila event, further extending the agenda to delegates who may not be able to travel to or within South Africa. Saphila 2023 is an opportunity for attendees, both in-person and those attending virtually, to connect, create and collaborate through knowledge sharing about innovations, implementation and service delivery best practices while being exposed to local customer testimonials and panel discussions covering eight different content streams – from platform & tech, transformation and human experience management to the future, next-gen services and more. Several world-class keynote speakers and top industry experts have been lined up to speak at the event, promising to deliver a content-rich learning experience. Additionally, the conference promises to deliver an all-encompassing immersive environment through providing access to exhibition spaces packed with SAP partners showcasing their solutions on implementing projects faster, better and within a cost-effective budget, as well as new product showcases and demonstrations presented by SAP and SAP partners. While virtual attendees may not be able to visit the physical partner exhibition, they will still be able to enjoy access to the Saphila 2023 virtual expo centre, which includes online booths for all exhibitors. They will also have the opportunity to participate in interactive sessions and live surveys. In this episode of TechCentral's TCS+ show, Louise Steenekamp, head of IT at Aspen Pharmacare -- speaking in her capacity as a board member of the African SAP User Group – unpacks what to expect at the upcoming Saphila 2023 event. The Saphila 2023 agenda is now live and can be accessed by visiting saphila2023.com/agenda. For more information and assistance with general event information and bookings, please send a message to info@SAPHILA2023.co.za. TechCentral

Stephen Saad, CEO at Aspen on their financial results and their vaccine deal with India's Serum Institute.    Colin Cullis in Business Unusual looked at refining productivity for remote work.    Then for Shapeshifter, Bruce Whitfield was joined by the CEO of SAB, Richard Rivett-Carnac talks about his career as well as the alcohol business. See omnystudio.com/listener for privacy information.

Guest: Stephen Saad | CEO at Aspen See omnystudio.com/listener for privacy information.

Stephen Saad – CEO, Aspen Pharmacare

Stavros Nicolaou – Senior Executive: Strategic Trade Development, Aspen Pharmacare Group

‘The Sygnia healthcare ETF is how I'd go into navigating offshore...[but] I believe that on the local market you will be getting good value with the three hospital groups and Aspen Pharmacare': Independent analyst Kea Nonyana.

Africa's top public health body has urged all those buying COVID-19 vaccines for the continent to place orders with South Africa's Aspen Pharmacare, saying the market was key to developing vaccine manufacturing on the continent. The Africa Centre for Disease Control and Prevention says it was doing everything it could behind the scenes to prevent a situation where Aspen closes its facility due to a lack of orders. A company executive says this was hailed as a game-changing moment for an under-vaccinated continent frustrated by sluggish Western handouts, but Aspen's COVID-19 vaccine plant now risks shutting down after receiving not a single order.

Aspen Pharmacare may have to shut its Gqeberha vaccination plant, which is meant to supply vaccines to the broader continent, due to a lack of vaccine orders. Business Day TV spoke to Stavros Nicolaou, Senior Executive on Strategic Trade at Aspen for more detail.

Glenn Orsmond, Co-CEO at Comair on rivals gouging prices while the airline was grounded. Miles van der Molen, CEO of CeMair disagreed with Orsmond's claim. Stefano Marani, CEO at Renergen on the company attracting another high-profile investor to its business. Stavros Nicolau, senior executive responsible for Strategic Trade Development at Aspen Pharmacare, talks about his relationship with money See omnystudio.com/listener for privacy information.

Philippe Auvaro is the former President of OrphanPacific Inc. of CMIC Holdings. Being born in the 60s, Mr. Auvaro grew up in a generation when Japan was experiencing the economic boom. He developed an appreciation of Japanese culture including classic movies, leading him to apply to an internship at a French pharmaceutical company called Roussel. Mr. Auvaro was eventually hired as a full-time staff at Roussel based in France, then worked for Aventis, which had gone through a merger with Sanofi in France. As Mr. Auvaro wanted to return to Japan, he then joined Glaxo SmithKline (GSK) Japan where he eventually became Executive Director. Most recently, Mr. Auvaro was the Managing Director, Senior Executive Officer of CMIC Holdings and President & Representative Director at OrphanPacific, Inc.   At GSK, Mr. Auvaro started as a Deputy Director in the Sales Division. He calls these years the “most amazing 11 years” of his life as he calls the organization “a school of empowerment.” Prior to his leadership role at GSK, Mr. Auvaro has experience in moving through the traditional Japanese management style ranks as well as working in a multicultural environment in both Europe and Japan. Mr. Auvaro explains his true “cross-cultural leadership experience” came when he was promoted to lead Roussel (which at that point had merged into Hoechst Marion Roussel) in Taiwan where he created the local office from scratch   Mr. Aurvaro's first major leadership role at GSK was leading a mega product for an antiasthma inhaler. There, Mr. Auvaro says he gained “field leadership” experience by working with people from various cultural background at the ground level, being in contact with every single part of the organization including manufacturing, R&D, and digital technology. Mr. Auvaro helped set up business units and create a shared service structure for the commercial operations such as helping start market research and call centres. Mr. Auvaro then got a secondment from GSK to work for Aspen PharmaCare, headquartered in South Africa, and was asked to help start Aspen in Japan.   After GSK, Mr. Auvaro was offered his most recent position at CMIC Group as OrphanPacitic Company's leader through a personal connection. At CMIC, Mr. Auvaro had been working on providing pharmaceutical solutions for rare disease challenges.   Mr. Auvaro describes his leadership as more “hardware than software” as he leans more towards directive leadership than being the recently popular “servant leader” type. Mr. Auvaro loves to be involved in the technical side of any product or service development and calls himself a fact-driven, field person. Mr. Auvaro defines leadership as a transaction between the leader and the employees. He says: “there is a fair amount of trust and delegation that people put in you. So you need to measure and scope and accept it, or redefine the scope.”

JSE Limited listed Aspen Pharmacare has concluded an agreement with Johnson and Johnson which will enable the pharmaceutical giant to manufacture and sell an Aspen-branded COVID-19 vaccine throughout Africa. Strictly Business

JSE Limited listed Aspen Pharmacare has concluded an agreement with Johnson and Johnson which will enable the pharmaceutical giant to manufacture and sell an Aspen-branded COVID-19 vaccine throughout Africa.

*After just a day, the Ballito Rage Festival has been cancelled. The annual event came to an abrupt end when party-goers and staff members tested positive for Covid-19. Despite strict protocol, including mandatory vaccination for staff and attendees, 32 guests and four staff members tested positive for the virus. The Department of Health was on-site and conducted contact tracing to ensure the isolation of those who tested positive. “We take the safety of all our customers, staff and suppliers extremely seriously. It is for this reason that the event organisers have taken the decision to cancel the remainder of Ballito Rage,” said organisers in a statement. *The start of 2022 could see the South African Government introduce a Covid-19 vaccine passport system. President Ramaphosa has said although the government will consider a vaccine mandate, it would not compel citizens to receive the inoculation against their will. A passport system would restrict access to areas and public services. *The Department of Mineral Resources and Energy has admitted to a mistake in the recently announced adjustments to the petrol price. Minister Gwede Mantashe said unleaded 93 and 95 petrol would increase by 81 cents on Wednesday. The price was supposed to go up by only 75 cents. In a statement, the department apologised for any inconvenience caused, noting it was the first time in the basic fuel price determination's history that it made this mistake. *South Africa's Aspen Pharmacare is hoping to produce its brand of Covid-19 vaccine. According to a statement released by the Durban-based company, Aspen is hoping to enter into a licensing agreement with Johnson and Johnson, with the intention of manufacturing the vaccine under the Aspenovax brand name. Aspen plans on selling it to a number of African states.

We chat to Stephen Saad - founder and chief executive of Aspen Pharmacare, the largest producer of generic medicines in Africa.

We chat to Stephen Saad - founder and chief executive of Aspen Pharmacare, the largest producer of generic medicines in Africa.

South Africa has asked Johnson & Johnson and Pfizer to delay delivery of Covid-19 vaccines because it now has too much stock, health ministry officials said, as vaccine hesitancy slows the inoculation campaign. About 35% of South Africans are fully vaccinated, higher than in most other African nations, but half the government's year-end target. It has averaged 106 000 doses a day in the past 15 days in a nation of 60-million people. Earlier this year the programme was slowed by insufficient doses. Now deliveries have been delayed due to oversupply, making the country an outlier in the continent where most are still starved of vaccines. Nicholas Crisp, deputy director-general of the Health Department, told Reuters that South Africa had 16.8-million doses in stock and said deliveries had been deferred. "We have 158 days' stock in the country at current use," a spokesperson for the Health Ministry said. "We have deferred some deliveries." They did not say when deliveries would now take place. Stavros Nicolaou, chief executive of Aspen Pharmacare, which is packaging 25-million doses a month of J&J vaccines in South Africa, said most of the vaccines bound for South Africa would now go to the rest of the continent. Nicolaou, who is also chairperson of public health at business lobby Business for South Africa (B4SA), said deliveries would likely be deferred until the first quarter of next year. Vaccines packaged at Aspen's plant are part of the African Union's agreement to buy 220-million doses from J&J. The AU and J&J did not respond to an email seeking comment. A Pfizer spokesperson said: "We remain adaptable to individual country's vaccine requirements whilst continuing to meet our quarterly commitments as per the South Africa supply agreement." South Africa's government has been seeking to boost the rate of daily administered doses. "There is a fair amount of apathy and hesitancy," said Shabir Madhi, who led the clinical study for the AstraZeneca Covid-19 vaccine in South Africa. To ramp up vaccinations, the government has launched pop-up vaccination centres and sought help from community leaders. It has also opened inoculations to children aged 12 to 17.

Aspen Pharmacare reports robust full year results and the group restores its dividend. The market reacts positivity.

Aspen Pharmacare reports robust full year results and the group restores its dividend. The market reacts positivity.

Die uitvoerende hoof van Aspen Pharmacare in Suid-Afrika, Stephen Saad, sê die maatskappy is trots op die rol wat hy speel in die vervaardiging van Covid-19-entstof vir verspreiding in Suid-Afrika en die res van die wêreld. Dit volg nadat Aspen bevestig het die eerste besending van die Johnson en Johnson-entstof is van sy hoof-vervaardigingsaanleg in die Oos-Kaap versend. Saad sê dis 'n reusestap vorentoe om te verseker dat Afrika sy gesondheidsprioriteite kan nakom:

Guest: Dr Keith Cloete | Head of Health at Western Cape Department Of Health In his address to the nation last night, President Cyril Ramaphosa said that the country is scheduled to receive around 31 million additional doses from Pfizer and Johnson & Johnson within the next 2 to 3 months. This supply pipeline, he said, means that there will be sufficient vaccine doses available for the rest of the year.  Today, Aspen Pharmacare said it will release the first batch of the J&J Covid-19 vaccines on Monday from its Gqeberha manufacturing site in the Eastern Cape. See omnystudio.com/listener for privacy information.

News headlines: *South Africa should aim to re-prioritise its budget to offset the cost of relief measures for businesses and individuals affected by deadly riots and accelerate reforms to foster inclusive economic growth. *An investigation into the social media campaign to incite violence and fuel the attempted insurrection this month has uncovered 12 Twitter accounts that were central to driving the unrest. *South Africa's largest pharmaceutical company Aspen Pharmacare will release the first batch of the Johnson & Johnson Covid-19 vaccines on Monday. 

News headlines: *South Africa should aim to re-prioritise its budget to offset the cost of relief measures for businesses and individuals affected by deadly riots and accelerate reforms to foster inclusive economic growth. *An investigation into the social media campaign to incite violence and fuel the attempted insurrection this month has uncovered 12 Twitter accounts that were central to driving the unrest. *South Africa's largest pharmaceutical company Aspen Pharmacare will release the first batch of the Johnson & Johnson Covid-19 vaccines on Monday. 

Die medisyne-vervaardiger, Aspen Pharmacare ,het vandag aangekondig dat dit die week dosisse van die Johnson en Johnson Covid-entstof aan Suid-Afrika sal vrystel. Die Aspen-fasiliteit in die Oos-Kaap het nie die dosisse vervaardig nie, maar wel gevul en afgerond met die aktiewe medisyne-bestanddele wat uit Europa ingevoer is. Ons Kaapse korrespondent, Fritz Platt, verduidelik.

As markets saw a strong start to the week off the back of ongoing developed market stimulus and vaccine rollouts, Arthur Karas discusses Aspen Pharmacare's results, amid some other positive company results. 

Die Uitvoerende Hoof van Aspen Pharmacare in Suid-Afrika Stephen Saad sê sowat 1 miljoen mense kan elke 4 dae in die buurland teen Covid-19 ingeënt word, sodra die beloofde dosisse van die Johnson & Johnson entstof van die Aspen Pharmacare fasiliteit in die Oos Kaap begin lewer word. Fritz Platt, Kosmos 94.1 Nuus se Kaapse Korrespondent het die besonderhede...

In this episode of the BizNews podcast dedicated to uncovering all the important news and views on the biggest public health crisis in living memory, we hear from Dr Simone Donati, who is among a team of scientists in Italy, about what medical experts have discovered on how the coronavirus goes easily undetected in normal Covid-19 tests by entering the human body through the eyes. We take an in-depth look at the latest developments on vaccine roll-out in South Africa, with an update on the government deals to secure jabs. You will also hear from CEO Stephen Saad about how South Africa's largest pharmaceuticals company, JSE-listed Aspen Pharmacare, has ramped up efforts to start rolling out J&J Covid-19 vaccines to South Africa and the rest of Africa within weeks. Later in the show, we share an update from Discovery Vitality about how novel measures to improve mental health as the pandemic takes its toll on our emotional wellbeing. Plus, the main Covid-19 news making world headlines this week - including more bad news for AstraZeneca.

In this episode of the BizNews podcast dedicated to uncovering all the important news and views on the biggest public health crisis in living memory, we hear from Dr Simone Donati, who is among a team of scientists in Italy, about what medical experts have discovered on how the coronavirus goes easily undetected in normal Covid-19 tests by entering the human body through the eyes. We take an in-depth look at the latest developments on vaccine roll-out in South Africa, with an update on the government deals to secure jabs. You will also hear from CEO Stephen Saad about how South Africa's largest pharmaceuticals company, JSE-listed Aspen Pharmacare, has ramped up efforts to start rolling out J&J Covid-19 vaccines to South Africa and the rest of Africa within weeks. Later in the show, we share an update from Discovery Vitality about how novel measures to improve mental health as the pandemic takes its toll on our emotional wellbeing. Plus, the main Covid-19 news making world headlines this week - including more bad news for AstraZeneca.

In this episode of the BizNews podcast dedicated to uncovering all the important news and views on the biggest public health crisis in living memory, we hear from Dr Simone Donati, who is among a team of scientists in Italy, about what medical experts have discovered on how the coronavirus goes easily undetected in normal Covid-19 tests by entering the human body through the eyes. We take an in-depth look at the latest developments on vaccine roll-out in South Africa, with an update on the government deals to secure jabs. You will also hear from CEO Stephen Saad about how South Africa's largest pharmaceuticals company, JSE-listed Aspen Pharmacare, has ramped up efforts to start rolling out J&J Covid-19 vaccines to South Africa and the rest of Africa within weeks. Later in the show, we share an update from Discovery Vitality about how novel measures to improve mental health as the pandemic takes its toll on our emotional wellbeing. Plus, the main Covid-19 news making world headlines this week - including more bad news for AstraZeneca.

In this episode of the BizNews podcast dedicated to uncovering all the important news and views on the biggest public health crisis in living memory, we hear from Dr Simone Donati, who is among a team of scientists in Italy, about what medical experts have discovered on how the coronavirus goes easily undetected in normal Covid-19 tests by entering the human body through the eyes. We take an in-depth look at the latest developments on vaccine roll-out in South Africa, with an update on the government deals to secure jabs. You will also hear from CEO Stephen Saad about how South Africa's largest pharmaceuticals company, JSE-listed Aspen Pharmacare, has ramped up efforts to start rolling out J&J Covid-19 vaccines to South Africa and the rest of Africa within weeks. Later in the show, we share an update from Discovery Vitality about how novel measures to improve mental health as the pandemic takes its toll on our emotional wellbeing. Plus, the main Covid-19 news making world headlines this week - including more bad news for AstraZeneca.

It's been a stressful period for the Aspen Pharmacare team as it moved at speed to deliver J&J vaccines for South Africa and the rest of Africa,knowing that every delay 'costs a life', says Stephen Saad, CEO of the only manufacturer in the southern hemisphere. 'People might dream of being the only player in the market but it's very stressful,' with the knowledge that so many lives are at stake. But this is also a watershed moment for the company. Saad spoke to BizNews editor-in-chief Jackie Cameron about what's been going on behind-the-scenes. JSE-listed Aspen Pharmacare has also provided dexamethasone and anaesthetics used in the fight against Covid-19, yet its share price hasn't risen as much as many might expect. Saad speaks about the big risk that J&J wouldn't pass clinical trials and why the company - which doesn't receive any funding from governments - isn't only focused on maximising profit. He shares details about the manufacturing process and why SA will catch up with vaccination roll-out. Aspen is providing 30m jabs of the one-dose shot to SA and expects to produce annual boosters; the SA government is also negotiating to buy vaccines from China, Russia and elsewhere. Aspen Pharmacare is the only producer in the southern hemisphere. #COVID19

It's been a stressful period for the Aspen Pharmacare team as it moved at speed to deliver J&J vaccines for South Africa and the rest of Africa,knowing that every delay 'costs a life', says Stephen Saad, CEO of the only manufacturer in the southern hemisphere. 'People might dream of being the only player in the market but it's very stressful,' with the knowledge that so many lives are at stake. But this is also a watershed moment for the company. Saad spoke to BizNews editor-in-chief Jackie Cameron about what's been going on behind-the-scenes. JSE-listed Aspen Pharmacare has also provided dexamethasone and anaesthetics used in the fight against Covid-19, yet its share price hasn't risen as much as many might expect. Saad speaks about the big risk that J&J wouldn't pass clinical trials and why the company - which doesn't receive any funding from governments - isn't only focused on maximising profit. He shares details about the manufacturing process and why SA will catch up with vaccination roll-out. Aspen is providing 30m jabs of the one-dose shot to SA and expects to produce annual boosters; the SA government is also negotiating to buy vaccines from China, Russia and elsewhere. Aspen Pharmacare is the only producer in the southern hemisphere. #COVID19

Gus Attridge – adjunk-hoof, Aspen Pharmacare

Nick Kuzne from Sanlam Private Wealth chose Aspen as his stock pick of the day and Mark du Toit from Oyster Catcher Investments chose Long4Life. Kunze said: "Aspen Pharmacare is my pic, I've been following it just on a pure valuation play. It's trading in single digits, obviously they're in the in the news and the press for the right reasons this time. The good news is that they've got their debt paid down significantly after selling the infant formula ​business and a few others. I think management are doing exactly what's asked and there is also the good news of them having to manufacture Johnson&Johnson 300 million doses of the vaccine. du Toit said: "My stock pick tonight is Long4Life. They've obviously had a very difficult trading time during Covid, and it has been very hard hit in the last six months. We think that they'll get back to their previous earnings levels of 43 cents a share fairly quickly."

In an effort to ensure small and medium-sized enterprises (SMEs) in South Africa survive the economic crisis, more than 50 large companies have formally committed to paying their SME suppliers within 30 days. The initiative, called #PayIn30, is spearheaded by Business for South Africa (B4SA), the South African SME Fund and Business Leadership South Africa (BLSA) and supported by, besides others, Business Unity South Africa (Busa), the Small Business Institute (SBI) and the Black Business Council (BBC). The recession and pandemic have severely impacted the country's 2.5-million small, medium and micro enterprises, which support about 10.8-million jobs. With a tightening economy, the benefits of the banks’ payment holidays coming to an end, and the winding down of the Temporary Employer/Employee Relief Scheme (TERS), this is expected to rise to 10% to 15% of small businesses going into business failure next year, with almost a million jobs lost and at risk. Even before the crisis, one of the key pressure points for SMEs was access to working capital and cash flow. This has a domino effect, as more than 20% of small businesses struggled to pay their staff and suppliers, and were denied access to finance because of poor cash flow. Covid-19 has exacerbated this problem. Some companies have used the crisis to extend payment terms and have asked SME suppliers to reduce fees, which is noted as unsustainable for smaller businesses. Corporate South Africa recognises that paying their SME suppliers within 30 days is one of the key levers for an SME’s sustainability, the initiative noted. “#PayIn30 is aimed at institutionalising a culture of early payments of SMEs. Over 50 companies have committed to this campaign and we expect this number to increase in the months to come. I am proud that our members recognise that we’re all in this together, and as corporate leaders, we need to do our part to help our economy grow,” said BLSA CEO Busi Mavuso. “We support unreservedly B4SA’s drive to ensure that corporates in South Africa pay SMEs within 30 days of receipt of invoice. Paying timeously is even more important in these difficult economic times when companies are struggling to maintain revenue. "AngloGold Ashanti hopes that by being part of this nationwide campaign, we can help raise awareness about how something as straightforward as paying invoices within 30 days can have a positive impact on SMEs. It will enable them to keep cash flow coming, helping them to weather the current economic storm. These businesses are not only providing goods and services, as well as adding to tax revenue, they also provide work for millions of people across the country and are of great value to South Africa,” said AngloGold Ashanti interim CEO Christine Ramon. “If there’s no money coming into an SME from its customers, there’s no money with which to pay their employees, lenders or their own suppliers. The knock-on effect of late payments reverberates across the economy. That’s why early payment terms for SMEs are critical. Aspen Pharmacare wholeheartedly supports B4SA’s #PayIn30 campaign and commits to paying all its SME suppliers within 30 days,” commented Aspen Pharmacare senior executive Stavros Nicoloau. “At our South Deep mine on the West Rand we support almost 80 suppliers from surrounding communities. Most of them are SMEs heavily reliant on work from us. It is therefore critical that we pay them within days after they have completed their job,” noted Gold Fields CEO Nick Holland. JSE CEO Leila Fourie said SMEs were key to the growth and development of the economy and play a fundamental, grassroots role in driving employment in our country. Many livelihoods are dependent on the success of these small businesses. "It’s for this reason that we, as the JSE, have pledged our support for the B4SA campaign, #PayIn30, which calls on corporate South Africa to play its part by committing to pay SME suppliers within 30 days. This ...

Intussen sê Ramaphosa ‘n doeltreffende en veilige entstof is die beste teenmiddel teen die koronavirus. Hy sê die wêreld se voorste farmaseutiese maatskappy, Johnson & Johnson, het ‘n voorlopige ooreenkoms aangegaan met ‘n plaaslike maatskappy, Aspen Pharmacare, vir die vervaardiging en verpakking van sy entstof by sy Nelson Mandelabaai-aanleg in die Oos-Kaap:

* A court has ruled against strict requirements of BEE in government tenders. * South Africa's manufacturing sector is showing signs of improvement. * The National Union of Metalworkers of SA is threatening legal action over the retrenchment process under way at Comair. This could scupper the business rescue process and trigger liquidation. * Aspen Pharmacare has agreed to manufacture the Covid-19 vaccine being developed by Johnson & Johnson at a factory in South Africa. The continent’s biggest drugmaker has the capacity to produce 300 million doses a year.

* A court has ruled against strict requirements of BEE in government tenders. * South Africa's manufacturing sector is showing signs of improvement. * The National Union of Metalworkers of SA is threatening legal action over the retrenchment process under way at Comair. This could scupper the business rescue process and trigger liquidation. * Aspen Pharmacare has agreed to manufacture the Covid-19 vaccine being developed by Johnson & Johnson at a factory in South Africa. The continent’s biggest drugmaker has the capacity to produce 300 million doses a year.

There's a possibility of a COVID-19 vaccine being manufactured on our shores. Aspen Pharmacare and Johnson & Johnson say they plan together to produce one.

Gus Attridge – CFO, Aspen Pharmacare

Gus Attridge – adjunk-hoof, Aspen Pharmacare

Stephen Saad, CEO of Aspen Pharmacare

Aspen Pharmacare has reached a preliminary agreement with Johnson & Johnson to manufacture the US company's Covid-19 vaccine should its clinical trials prove successful. The production will be done at Aspen's Port Elizabeth facility. Business Day TV spoke to the drugmaker's CEO Stephen Saad for more detail on the agreement and what it could potentially mean for the company's growth prospects.

Low-cost carrier Ryanair posts first summer loss in decades Ryanair has reported a loss for its key summer period for the first time in 30 years as the pandemic hit air travel demand. The low-cost carrier lost 230-million- dollars in the six months to September, driven by an 80-percent drop in passenger numbers. The company has also warned of bigger losses as a resurgence of infections sparks new lockdowns across Europe. Aspen to manufacture J&J COVID-19 vaccine in South Africa South African drugmaker, Aspen Pharmacare, has agreed to manufacture the COVID-19 vaccine candidate being developed by Johnson & Johnson. The potential vaccine is still in clinical trials, and if approved, will be made and packaged at Aspen's plant in Port Elizabeth. Shares in Aspen rose more than 5-percent after the announcement. Turkish manufacturing recovery picks up pace in October Turkey's manufacturing activity grew for a fifth straight month with sharp upticks in orders and output. The Purchasing Managers' Index for manufacturers rose to 53-point-9 in October, from 52-point-8 in the previous month. Meanwhile, a separate report showed Turkey's exports rose 5-point-6 percent to a record high of 17-point-3 billion dollars in the same month.

BizNews — Aspen Pharmacare has been through a difficult phase of restructuring but the pharmaceutical giant is in great shape, especially with the latest sale of its thrombosis unit to Mylan. With Covid-19 wreaking havoc, Aspen is also in a great position with the production and distribution of the life-saving drug Dexamethasone. BizNews founder Alec Hogg was joined by CEO Stephen Saad during his Rational Radio webinar to discuss Aspen's excellent preliminary results as well as his desire to take Aspen further into vaccine territory. Market commentator David Shapiro and Adrian Saville of Cannon Asset Managers also joined the fascinating discussion.

BizNews — Aspen Pharmacare has been through a difficult phase of restructuring but the pharmaceutical giant is in great shape, especially with the latest sale of its thrombosis unit to Mylan. With Covid-19 wreaking havoc, Aspen is also in a great position with the production and distribution of the life-saving drug Dexamethasone. BizNews founder Alec Hogg was joined by CEO Stephen Saad during his Rational Radio webinar to discuss Aspen's excellent preliminary results as well as his desire to take Aspen further into vaccine territory. Market commentator David Shapiro and Adrian Saville of Cannon Asset Managers also joined the fascinating discussion.

Stephen Saad: Unplugged. The Aspen Pharmacare CEO opens up to Lindsay Williams about a reshaped company that's poised for greatness. Results with Stephen Saad - CEO of Aspen Pharmacare

Stephen Saad: Unplugged. The Aspen Pharmacare CEO opens up to Lindsay Williams about a reshaped company that's poised for greatness. Results with Stephen Saad - CEO of Aspen Pharmacare

Moneyweb Radio — Gus Attridge – Deputy CE, Aspen Pharmacare

Moneyweb Radio — Stephen Saad – CEO, Aspen Pharmacare

In episode 49 of Inside Covid-19, good news if you're a careful driver or have a well-run small business; why remote doctor consults (telemedicine) is here to stay; an update on the search for an effective way to identify those with Covid-19 antibodies; the CEO of Sun International explains what the opening up of hotels means for the group on whom 20,000 livelihoods depend; and we take another look at Dexamethasone, the anti-inflammatory drug made in South Africa by Aspen Pharmacare, which is being hailed globally as a breakthrough saving the lives of 30% of critically ill coronavirus patients during a large trial in the UK. - Alec Hogg

BizNews — In episode 49 of Inside Covid-19, good news if you’re a careful driver or have a well-run small business; why remote doctor consults (telemedicine) is here to stay; an update on the search for an effective way to identify those with Covid-19 antibodies; the CEO of Sun International explains what the opening up of hotels means for the group on whom 20,000 livelihoods depend; and we take another look at Dexamethasone, the anti-inflammatory drug made in South Africa by Aspen Pharmacare, which is being hailed globally as a breakthrough saving the lives of 30% of critically ill coronavirus patients during a large trial in the UK. - Alec Hogg

BizNews — In episode 49 of Inside Covid-19, good news if you’re a careful driver or have a well-run small business; why remote doctor consults (telemedicine) is here to stay; an update on the search for an effective way to identify those with Covid-19 antibodies; the CEO of Sun International explains what the opening up of hotels means for the group on whom 20,000 livelihoods depend; and we take another look at Dexamethasone, the anti-inflammatory drug made in South Africa by Aspen Pharmacare, which is being hailed globally as a breakthrough saving the lives of 30% of critically ill coronavirus patients during a large trial in the UK. - Alec Hogg

In episode 49 of Inside Covid-19, good news if you're a careful driver or have a well-run small business; why remote doctor consults (telemedicine) is here to stay; an update on the search for an effective way to identify those with Covid-19 antibodies; the CEO of Sun International explains what the opening up of hotels means for the group on whom 20,000 livelihoods depend; and we take another look at Dexamethasone, the anti-inflammatory drug made in South Africa by Aspen Pharmacare, which is being hailed globally as a breakthrough saving the lives of 30% of critically ill coronavirus patients during a large trial in the UK. - Alec Hogg

Moneyweb Radio — Stephen Saad – CEO, Aspen Pharmacare

Moneyweb Radio — Stephen Saad – uitvoerende hoof, Aspen Pharmacare

Andrew Skipper is the Head of Hogan Lovells Africa Practice. Since taking on this role six years ago, he has met and formed close relationships with some of Africa's most influential leaders, both on and off the continent. Listen to Andrew's interview with one of Africa's leading industrialists, Kuseni Dlamini, Chairman of JSE-listed Massmart and Aspen Pharmacare. Hear first-hand what the man at the helm of two of Africa's industry giants in the retail and pharmaceutical sectors, has to say about putting staff first in a crisis, staying nimble as a business and the opportunities of the AfCFTA.

South African businessman Kuseni Dlamini is the Chairman of two JSE-listed companies, Massmart and Aspen Pharmacare, with a combined turnover of nearly $10bn. He is thinking big for South African companies, and wants them to take on the world. “Eskom should be a global energy giant, that can go and build power plants in England.”

Business Day TV — Steven Schultz from Momentum chose Aspen Pharmacare as his stock pick of the day. "Its Aspen, it's a counter that's effectively halved in value over the past twelve months. There's been a number of reasons why, most notably debt buildup and shareholders are obviously uncomfortable with that. We've seen not a lot of assistance come through in the form of a slight decline in earnings and revenue. The company has of course disposed of assets and paid down some debt. It was previously at about fifty three billion rands worth of debt, today sits at about thirty nine billion so, definitely making headway in paying off their debt. It is also transforming the company, its European operations are currently under strategic review and it is transforming across from a generics business into a sterile injectables business. There are many that have criticized its organic grow

Moneyweb Radio — Stephen Saad – CEO, Aspen Pharmacare

It’s now common cause that the report circulated by Viceroy Research brought down the 90 000 employee-strong Steinhoff. The report exposed the accounting irregularities which Steinhoff eventually owned up to. Viceroy, a shadowy firm with just three full time employees but an army of followers, has another South African company in its sights. On Tuesday, its Twitter account that has just over 5 000 followers said the Viceroy report on this company would be released before the end of March. On the Johannesburg Stock Exchange, Mr Market went crazy. Speculation that it was Viceroy’s target smashed the prices of multinational Aspen Pharmacare and three JSE-listed property stocks. In today’s episode of the Old Firm, David Shapiro and I examine what’s become known among traders as The Viceroy Effect.

It’s now common cause that the report circulated by Viceroy Research brought down the 90 000 employee-strong Steinhoff. The report exposed the accounting irregularities which Steinhoff eventually owned up to. Viceroy, a shadowy firm with just three full time employees but an army of followers, has another South African company in its sights. On Tuesday, its Twitter account that has just over 5 000 followers said the Viceroy report on this company would be released before the end of March. On the Johannesburg Stock Exchange, Mr Market went crazy. Speculation that it was Viceroy’s target smashed the prices of multinational Aspen Pharmacare and three JSE-listed property stocks. In today’s episode of the Old Firm, David Shapiro and I examine what’s become known among traders as The Viceroy Effect.

TOP STORIES ON AFRICA RISE AND SHINE THIS HOUR... *** South Africa condemns deadly bomb blasts in Mogadishu.... *** Burundi accuses Rwanda and Belgium of distabilizing the country... *** DRC government briefs SADC chair on election preparations..... *** In Economics: UK anti-trust regulator investigates Aspen Pharmacare... *** And In Sports: Morocco to replace Kenya as hosts of African Nations Championship..

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: QuintilesIMS, Teva Pharmaceutical Industries, Mylan, Novartis, Sandoz, Pfizer, Allergan, Sun Laboratories, Fresenius, Endo International, Lupin, Sanofi, Aspen Pharmacare, Aurobindo, Cipla, Apotex, Dr. Reddy's, Ypsomed.Persone: Alessandro Mostaccio (Movimento dei consumatori), Federico Spandonaro (Università Tor Vergata di Roma), Andrea Giustina (Università Vita e Salute San Raffaele), Annamaria Vezzani (Istituto Mario Negri di Milano), Pier Paolo di Fiore (IFOM), Sara Sigismund (Università Statale di Milano), Carlo Tacchetti (Ospedale San Raffaele di Milano), Giancarlo Agnelli (Università di Perugia), Andrea Fontanella (FADOI), Massimo Galli (Università degli Studi di Milano), François Houÿez (EURORDIS), Marco Romano (Chiltern International). Nuove terapie: elbasvir/grazoprevir.Patologie: allergie, diabete, epilessia, cancro, tromboembolismo, epatite C.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: QuintilesIMS, Teva Pharmaceutical Industries, Mylan, Novartis, Sandoz, Pfizer, Allergan, Sun Laboratories, Fresenius, Endo International, Lupin, Sanofi, Aspen Pharmacare, Aurobindo, Cipla, Apotex, Dr. Reddy's, Ypsomed.Persone: Alessandro Mostaccio (Movimento dei consumatori), Federico Spandonaro (Università Tor Vergata di Roma), Andrea Giustina (Università Vita e Salute San Raffaele), Annamaria Vezzani (Istituto Mario Negri di Milano), Pier Paolo di Fiore (IFOM), Sara Sigismund (Università Statale di Milano), Carlo Tacchetti (Ospedale San Raffaele di Milano), Giancarlo Agnelli (Università di Perugia), Andrea Fontanella (FADOI), Massimo Galli (Università degli Studi di Milano), François Houÿez (EURORDIS), Marco Romano (Chiltern International). Nuove terapie: elbasvir/grazoprevir.Patologie: allergie, diabete, epilessia, cancro, tromboembolismo, epatite C.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

Today in FirstWord:

'Aspen has grown rapidly after expanding outside its highly regulated home market' - Stephen Saad - CEO, Aspen Pharmacare www.moneyweb.co.za

Moneyweb Radio — 'Aspen has grown rapidly after expanding outside its highly regulated home market' - Stephen Saad - CEO, Aspen Pharmacare

Today in FirstWord: